DME Capital Management’s Viatris VTRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.6M Buy
+1,817,570
New +$25.4M 0.77% 34
2025
Q2
Sell
-6,000,830
Closed -$52.3M 37
2025
Q1
$52.3M Buy
6,000,830
+215,720
+4% +$2.26M 2.65% 13
2024
Q4
$72M Sell
5,785,110
-1,485,320
-20% -$18.3M 3.7% 8
2024
Q3
$84.4M Sell
7,270,430
-129,380
-2% -$1.49M 3.51% 9
2024
Q2
$78.7M Buy
7,399,810
+2,882,190
+64% +$31.8M 3.85% 10
2024
Q1
$53.9M Buy
+4,517,620
New +$54.4M 2.47% 11

Other funds holding VTRS

DME Capital Management's VTRS Position: Q1 2026 in Review

DME Capital Management opened a new position in Viatris (VTRS) in Q1 2026: 1,817,570 shares worth $24.6M. The stake represents 0.77% of the portfolio and ranks #34 among its holdings. This is a return to the name: DME Capital Management previously reported a position in VTRS as recently as Q1 2025.

DME Capital Management first reported a position in VTRS in Q1 2024 and has held it in 6 quarters since. The position peaked at $84.4M in Q3 2024. 1,019 funds tracked by Wall St. Rank hold VTRS as of Q1 2026.

  • DME Capital Management held 1,817,570 shares of Viatris worth $24.6M as of Q1 2026.
  • Viatris was a new DME Capital Management position in Q1 2026.
  • Viatris made up 0.77% of DME Capital Management's portfolio in Q1 2026, its #34 holding.
  • DME Capital Management first reported a position in Viatris in Q1 2024 and has held it in 6 quarters since.
  • DME Capital Management's Viatris position peaked at $84.4M in Q3 2024.
  • 1,019 funds tracked by Wall St. Rank held Viatris as of Q1 2026.

Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.